Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD, and Safety of SHR8735 in Healthy Chinese and Caucasian Subjects
NCT04701216Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Feb 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hetrombopag in Thrombocytopenia (3 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Adverse events at 28 days. Started Feb 2021; status: completed.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04701216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701216.